Medical/Pharmaceuticals

Leading Chinese Innovative Medical Device Maker Insight Lifetech Has Successfully Listed on STAR Market

SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Insight Lifetech, a portfolio company of Qiming Venture Partners and a leading Chinese innovative medical device manfaucturer, successfully listed on the Shanghai Stock Exchange's STAR Market on February 5, 2026 Beijing time. Insight Lifetech (688712.SH) iss...

2026-02-05 19:39 3987

HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026

Sustained execution and high-impact data across HanchorBio's next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC TAIPEI and SHANGHAI and SAN FRANCISCO, Feb. 4, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechno...

2026-02-05 17:09 4485

Galaxy Brain Scientific's Technology Enables Landmark Parkinson's Study Published in Nature, Redefining Disease Mechanism

BEIJING, Feb. 5, 2026 /PRNewswire/ -- A research team led by Prof. Hesheng Liu, founder and Chief Scientific Officer of Galaxy Brain Scientific Inc., has published a study inNature that pinpoints the core functional circuit underlying Parkinson's disease (PD). The findings redefine the biological...

2026-02-05 13:00 3805

Moleac is pleased to announce that NeuroAiD™II has been awarded Gold accreditation by Empowered By Evidence.

SINGAPORE, Feb. 5, 2026 /PRNewswire/ -- This recognition reflects the robust clinical evidence supporting NeuroAiD™II, as well as the uniqueness of its formulation, the rigour of its manufacturing, reproducibility, and quality control, highlighting its reliability and value in supporting neurolog...

2026-02-05 11:48 5275

Asian Smart Medical Online Exhibition 2026: Connecting Smart Medical Suppliers with Global Buyers

TAIPEI, Feb. 5, 2026 /PRNewswire/ -- The Asian Smart Medical Online Exhibition 2026 (Medical Asia 2026) is a premier hybrid exhibition designed to seamlessly connect Asian medical suppliers, importers, and exporters with buyers from around the world. Taking place from February 3, 2026, to May 31,...

2026-02-05 09:05 3910

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive ...

2026-02-05 08:17 3625

Yuyu Pharma Invests in James & Ella, Advancing Its Global Expansion Into Premium Pet Wellness

SEOUL, South Korea, Feb. 4, 2026 /PRNewswire/ -- Yuyu Pharma announced today a strategic investment in James & Ella, theUnited Kingdom's fastest-growing freeze-dried pet nutrition company. Founded by entrepreneurJames Middleton, James & Ella has rapidly established itself as the leader of the UK ...

2026-02-04 22:00 3649

Providence Therapeutics Announces World-First Personalized Pediatric mRNA Cancer Vaccine Trial

Landmark Australian study opens new possibilities for children with aggressive brain tumors and signals opportunity for Canada and USA. CALGARY, AB and BRISBANE, Australia , Feb. 5, 2026 /PRNewswire/ -- Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, is supporting ...

2026-02-04 21:00 3630

NCCN Commemorates World Cancer Day with New Commitment to Update Patient Resources

The National Comprehensive Cancer Network pledges to update robust information resources for cancer patients and caregivers on an annual basis in both English and Spanish. PLYMOUTH MEETING, Pa., Feb. 4, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leadin...

2026-02-04 20:04 2485

Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profi...

2026-02-04 08:01 6080

Telix Full Year Results 2025 Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") advises that it will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026 AEDT (Thursday 19 February 2026 EST). An invest...

2026-02-04 05:38 4538

Role of CathWorks FFRangio for the Assessment of Coronary Artery Disease Now Reinforced by SCAI Expert Opinion

NEWPORT BEACH, Calif., Feb. 4, 2026 /PRNewswire/ -- CathWorks, a global leader in digital health innovations, announced that the Society for Cardiovascular Angiography & Interventions (SCAI) published an expert opinion discussing the expanding role of angiography-derived physiology (ADP), a wire-...

2026-02-04 02:05 4195

United Imaging Healthcare North America Welcomes John Campbell as Vice President of Customer Success

HOUSTON, Feb. 3, 2026 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy solutions, is pleased to announce that John Campbell recently joined the organization as Vice President of Customer Success,North America. In this role, he will support United Imaging...

2026-02-04 01:00 3650

Metabolon Names Andrew Messick Chief Financial Officer

Seasoned life sciences finance leader brings deep expertise in operational excellence and M&A to support Metabolon's next stage of growth MORRISVILLE, N.C., Feb. 3, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life scienc...

2026-02-03 22:00 3450

Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501

Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone payment ofUSD 5 million from Menarini Group after first-in-patient dosing in a Phase 1 trial of MEN2501, highly differentiated small molecule KIF18A inhibitor in d...

2026-02-03 22:00 5411

Akso Health Group Announces Launch of Exploratory Global Patient Support Initiative

QINGDAO, China, Feb. 3, 2026 /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the launch of the an exploratory patient support program and a strategic cooperation with Nanning Duoling Research Institute. Adopting an integrated model of "Traditional ...

2026-02-03 22:00 6563

NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer

NEW YORK, Feb. 3, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.    NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nea...

2026-02-03 21:58 6479

CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access

OSLO, Norway and INCHEON, South Korea, Feb. 3, 2026 /PRNewswire/ -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced a partnership to strengthen vaccine manufact...

2026-02-03 21:00 4905

Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid Tumors

Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In Global, For Global" collaboration strategy. NEWARK, Del. and NANJING, China, Feb. 3, 2026 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a globa...

2026-02-03 17:31 4154

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an inn...

2026-02-03 11:22 4606
1234567 ... 646